Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Exclusion Criteria

• •Ability to understand and willingness to sign the written informed consent document
• •Human immunodeficiency virus (HIV) infection without acquired immune deficiency syndrome (AIDS)-defining criteria are eligible
• •DONOR: Donors must be human leukocyte antigen (HLA)-haploidentical first-degree relatives of the patient; eligible donors include biological parents, siblings or half-siblings, or children
• •DONOR: Donor must be in general good health and eligible for apheresis as determined by the medical provider
• •DONOR: HLA-haploidentical donor/recipient match by at least class I serologic typing at the HLA-A and B loci
• •DONOR: Willing and able to provide informed consent
• •Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
• •Patients receiving any other investigational agents or patients that have received other investigational agents within 14 days of enrollment
• •Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managed
• •Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; as infection is a common feature of AML, patients with active infection are permitted to enroll provided that the infection is under control
• •Patients with serious medical or psychiatric illness likely to interfere with participation in this clinical study
• •Pregnant women or women who are breastfeeding are excluded from this study; confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women
• •Patients with metastatic malignant solid tumors who received treatment in the past 6 months are excluded
• •DONOR: Pregnancy
• •DONOR: HIV